5 Healthcare Stocks to Buy According to Lee Ainslie’s Maverick Capital

Page 1 of 5

In this piece, we will take a look at the 5 healthcare stocks to buy according to Lee Ainslie’s Maverick Capital. If you want to learn more about Mr. Ainslie and his hedge fund, alongside other stocks that he has bought, take a look at 10 Healthcare Stocks to Buy According to Lee Ainslie’s Maverick Capital.

5. Nektar Therapeutics (NASDAQ:NKTR)

Maverick Capital’s Stake Value: $104 million

Percentage of Maverick Capital’s 13F Portfolio: 1.05%

Number of Hedge Fund Holders: 23

Nektar Therapeutics (NASDAQ:NKTR) is an American biotechnology company that is developing products for several diseases. Its products aim to target several types of cancers such as those of the liver, bladder, and urethra. Additionally, it is also developing a treatment for the COVID-19 coronavirus.

Nektar Therapeutics (NASDAQ:NKTR) substantially missed its revenue estimates for fiscal Q3, by posting $24.9 million in the segment. However, the company’s GAAP EPS of -$0.70 beat analyst estimates by $0.10. BTIG slashed its price target for the firm to $54 from $80 in November 2021 following the earnings report, explaining that reduced revenue estimates from a treatment trial influenced the decision.

Mr. Ainslie’s Maverick Capital owned 5.8 million Nektar Therapeutics (NASDAQ:NKTR) shares as the third quarter of this year came to an end. These were worth $104 million and represented 1.05% of its investment portfolio. Insider Monkey’s Q3 2021 poll of 867 hedge funds revealed that 23 owned a stake in the firm.

Nektar Therapeutics (NASDAQ:NKTR)’s largest investor after Maverick Capital is Stephen Dubois’ Camber Capital Management who owns 3.7 million shares worth $67 million.

Page 1 of 5